$MCK

Rodgers Thomas L sold $1.8M of MCK

Rodgers Thomas L (EVP, Chief Strategy & BDO) sold 2,388 shares of MCKESSON CORP (MCK) at $761.09 ($1.82M total) on 2026-05-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rodgers Thomas L
Published May 27, 2026, 6:12 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 6:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MCK
Neutral
medium confidence
Mentioned
$MCK
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MCKNeutralLow
01

Why it matters

The disclosed sale may attract short-term attention, but 10b5-1 pre-arrangement generally lowers the probability that the trade reflects new, material negative information.

02

Market read

A single officer sale under a 10b5-1 plan is typically a low-signal event for trading, absent other catalysts.

03

What to watch

The article provides only one sale; without additional context (e.g., buys, option exercises, or subsequent filings), directional inference is weak.

Relevance 6/10Timing: Immediate (same-day disclosure) but informationally limited due to 10b5-1 context.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for McKesson (MCK).

Company-level read

Ticker impact

$MCKNeutralMedium confidence
Context

McKesson Form 4 shows EVP Thomas L. Rodgers sold 2,388 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be muted unless accompanied by other company-specific news.

Evidence & confidence

The filing is an SEC Form 4 insider transaction with a stated 10b5-1 plan, which typically indicates planned liquidity rather than new negative information.

Market effects

Minimal; this is company-specific insider liquidity disclosure with no sector-wide catalyst mentioned.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider sales can still coincide with valuation or risk management motives; monitor for clustering of similar filings.

Key entities

  • McKesson Corp

    Subject of the Form 4 insider transaction disclosure (EVP Thomas L. Rodgers sale).

  • Rodgers Thomas L

    EVP, Chief Strategy & BDO who sold shares under a pre-arranged 10b5-1 plan.

Related articles

$MCKMed

McKesson Q1 Earnings Call Highlights

McKesson (NYSE: MCK) reported Q1 results supported by higher prescription and specialty volumes, partially offset by lower branded-drug pricing. GLP-1 distribution revenue rose to $15B, up about $3B (24%). Full-year guidance calls for North American Pharmaceutical revenue growth of 4% to 8%. Oncology & Multispecialty profit rose 41% to $405M. McKesson repurchased $2.5B shares and expects FY27 FCF $4.5B to $4.9B.

$MCKMedAI 8/10

Highlights of McKesson’s (MCK) Q1 2027 earnings report

McKesson (MCK) reported Q1 fiscal 2027 results. Adjusted earnings rose to $9.93 per share from $8.26 a year earlier, beating analysts. Unadjusted net income was $614 million, or $5.17 per share. Revenue increased to $105.4 billion from $97.83 billion. The company raised FY27 adjusted EPS guidance to $44.20 to $45.00.

$MCKHighAI 9/10

[MCK Q1 2027 Earnings Call] McKesson Lifts Full-Year EPS Target as North American Pharma Profit Soars 19% — BigGo Finance

McKesson reported fiscal Q1 2027 revenue of $105.4B, up 8%, and adjusted EPS of $9.93, up 20%, citing stronger North American Pharmaceutical margins. North American Pharma operating profit rose 19% to $894M on 5% revenue growth, with GLP-1 distribution revenue at $15B (+24%). McKesson raised full-year adjusted EPS guidance to $44.20–$45.00 and returned $2.6B to shareholders.